secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001171843-25-001105
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics reports FY2024 net loss of $49.4M; tovecimig data expected end Q1 2025
--------------------------------------------------------------------------------

- Net loss $49.4M ($0.36/shr) vs $42.5M ($0.33) in 2023; R&D expense $42.3M (+11%).
- Cash and marketable securities $127M, down from $152M; cash runway into 2027.
- Top-line data from COMPANION-002 (tovecimig in BTC) on track for end of Q1 2025.
- Phase 2 trials for tovecimig in DLL4+ CRC and CTX-471 in NCAM+ tumors expected mid-2025.
- CTX-10726 IND filing expected year-end 2025; CTX-8371 Phase 1 third cohort enrolled, no DLTs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325001105/0001171843-25-001105-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184325001105/f8k_022625.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001105

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer